Figure 1 Figure 2 To be diagnosed with GWS, the Centers for Disease Control and Prevention (CDC) criteria for Chronic Multisymptomatic Illness (CMI) require symptoms from at least two of the three symptom clusters: general fatigue, mood and cognitive abnormalities, and myalgia/athralgia pain (Fukuda et al., 1998)
Entre ellos se encuentran semaglutida (Ozempic para diabetes, Wegovy para control de peso), liraglutida (Victoza para diabetes, Saxenda para control de peso), dulaglutida (Trulicity, solo para diabetes) y tirzepatida (Mounjaro para diabetes, Zepbound para control de peso), siendo esta ltima un agonista dual que acta sobre los receptores GIP y GLP-1
Researchers commonly investigate: Molecular structure and composition
BI 456906: discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy